We will see what the testing shows at the government labs.
I suspect the value of defensins whether they are theta, alpha, beta,human, mimetic or other will be in their immunomodulating effects rather than direct antiviral effects.
The link below is to a retrospective review of MERS treatment at a middle eastern hospital. It is an excellent review and their statistics show the treatment most associated with survival was the anti-inflammatory and anti-rejection drug,mycophenolate mofetil. It was only used in 8 patients and the authors stated it was used in the MERS patients who were less ill, but the numbers are impressive. They may correlate with the observation of severe pulmonary inflammation and fibrosis in Coronaviral respiratory failure.
The fact the labs seemed to reach out to IPIX means to me they are very interested in testing Brilacidin to see if it will increase survival the way the theta defensin did in the murine SARS model and mycophenolate mofetil did in the MERS group.The fact that Brilacidin has proven to be safe in all the trials and successfully finished its FDA phase 2 ABSSSI trial have to be points in its favor
Mr Ehlich mentioned the were looking to study Brilacidin in different drug combinations looking for synergies.
I would expect them to couple Brilacidin with an antiviral but again we will have to wait and see.
It would be interesting to see who is helping writing the Blog and PR. He must have his plate full.
Market Data 
Markets 
AI
